292 related articles for article (PubMed ID: 34861342)
21. A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist.
Payrits M; Sághy É; Mátyus P; Czompa A; Ludmerczki R; Deme R; Sándor Z; Helyes Z; Szőke É
Neuroscience; 2016 Jun; 324():151-62. PubMed ID: 26930003
[TBL] [Abstract][Full Text] [Related]
22. Modification of the TRP Channel TRPA1 as a Relevant Factor in Migraine-Related Intracranial Hypersensitivity.
Masood T; Lakatos S; Rosta J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982450
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the role of lipid rafts and sphingomyelin in Ca2+-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals.
Sághy É; Szőke É; Payrits M; Helyes Z; Börzsei R; Erostyák J; Jánosi TZ; Sétáló G; Szolcsányi J
Pharmacol Res; 2015 Oct; 100():101-16. PubMed ID: 26238178
[TBL] [Abstract][Full Text] [Related]
24. Emerging Perspectives on Pain Management by Modulation of TRP Channels and ANO1.
Takayama Y; Derouiche S; Maruyama K; Tominaga M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336748
[TBL] [Abstract][Full Text] [Related]
25. Activation characteristics of transient receptor potential ankyrin 1 and its role in nociception.
Raisinghani M; Zhong L; Jeffry JA; Bishnoi M; Pabbidi RM; Pimentel F; Cao DS; Evans MS; Premkumar LS
Am J Physiol Cell Physiol; 2011 Sep; 301(3):C587-600. PubMed ID: 21653898
[TBL] [Abstract][Full Text] [Related]
26. Modulation of Glia Activation by TRPA1 Antagonism in Preclinical Models of Migraine.
Demartini C; Greco R; Magni G; Zanaboni AM; Riboldi B; Francavilla M; Nativi C; Ceruti S; Tassorelli C
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430567
[TBL] [Abstract][Full Text] [Related]
27. Mechanosensitive meningeal nociception via Piezo channels: Implications for pulsatile pain in migraine?
Mikhailov N; Leskinen J; Fagerlund I; Poguzhelskaya E; Giniatullina R; Gafurov O; Malm T; Karjalainen T; Gröhn O; Giniatullin R
Neuropharmacology; 2019 May; 149():113-123. PubMed ID: 30768945
[TBL] [Abstract][Full Text] [Related]
28. Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels.
Kleeberg-Hartmann J; Vogler B; Messlinger K
J Headache Pain; 2021 Apr; 22(1):23. PubMed ID: 33849430
[TBL] [Abstract][Full Text] [Related]
29. TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities.
Benemei S; Dussor G
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30970581
[TBL] [Abstract][Full Text] [Related]
30. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.
Materazzi S; Fusi C; Benemei S; Pedretti P; Patacchini R; Nilius B; Prenen J; Creminon C; Geppetti P; Nassini R
Pflugers Arch; 2012 Apr; 463(4):561-9. PubMed ID: 22258694
[TBL] [Abstract][Full Text] [Related]
31. Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model.
Demartini C; Greco R; Zanaboni AM; Francesconi O; Nativi C; Tassorelli C; Deseure K
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366396
[TBL] [Abstract][Full Text] [Related]
32. The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model.
Demartini C; Tassorelli C; Zanaboni AM; Tonsi G; Francesconi O; Nativi C; Greco R
J Headache Pain; 2017 Sep; 18(1):94. PubMed ID: 28884307
[TBL] [Abstract][Full Text] [Related]
33. Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain.
Tajti J; Szok D; Csáti A; Szabó Á; Tanaka M; Vécsei L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835524
[TBL] [Abstract][Full Text] [Related]
34. Ion Channels of Nociception.
Giniatullin R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443485
[TBL] [Abstract][Full Text] [Related]
35. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine.
Messlinger K; Fischer MJ; Lennerz JK
Keio J Med; 2011; 60(3):82-9. PubMed ID: 21979827
[TBL] [Abstract][Full Text] [Related]
36. TRP channels in cancer pain.
de Almeida AS; Bernardes LB; Trevisan G
Eur J Pharmacol; 2021 Aug; 904():174185. PubMed ID: 34015320
[TBL] [Abstract][Full Text] [Related]
37. TRP channels and analgesia.
Premkumar LS; Abooj M
Life Sci; 2013 Mar; 92(8-9):415-24. PubMed ID: 22910182
[TBL] [Abstract][Full Text] [Related]
38. TRP channels: potential drug target for neuropathic pain.
Marwaha L; Bansal Y; Singh R; Saroj P; Bhandari R; Kuhad A
Inflammopharmacology; 2016 Dec; 24(6):305-317. PubMed ID: 27757589
[TBL] [Abstract][Full Text] [Related]
39. Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity.
Balemans D; Boeckxstaens GE; Talavera K; Wouters MM
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G635-G648. PubMed ID: 28385695
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.
Giniatullin R; Nistri A; Fabbretti E
Mol Neurobiol; 2008 Feb; 37(1):83-90. PubMed ID: 18459072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
